For the past 2 decades, multiple studies have reported an overarching tumor suppressor role of DYRK2 across various cancers (reviewed in Yoshida and Yoshida [27]), with antitumorigenic roles including regulation of cell cycle, apoptosis, epithelial–mesenchymal transition (EMT), cancer stemness, and antimetastatic roles (reviewed in Yoshida and Yoshida [27]). Here, DYRK2 is linked to neoplasm.